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Objective: To analyze the results of the application of the Bath Ankylosing Spondylitis Dis-
ease Activity Index (BASDAI) in a large series of Brazilian patients with the diagnosis of SpA
and  establish its correlations with speciﬁc variables into the group.
Methods: A common protocol of investigation was prospectively applied to 1492 Brazilian
patients classiﬁed as SpA according to the European Spondyoarthropathies Study Group
(ESSG), attended at 29 referral centers of Rheumatology in Brazil. Clinical and demographic
variables, and disease indices (BASDAI, Basﬁ, Basri, Mases, ASQol) were applied. The total
values of BASDAI were compared to the presence of the different variables.
Results: The mean score of BASDAI was 4.20 ± 2.38. The mean scores of BASDAI were higher
in  patients with the combined (axial + peripheral + entheseal) (4.54 ± 2.38) clinical presen-
tation, compared to the pure axial (3.78 ± 2.27) or pure peripheral (4.00 ± 2.38) clinical
presentations (P < 0.001). BASDAI also presented higher scores associated with the female
gender (P < 0.001) and patients who did not practice exercises (P < 0.001). Regarding the axial
component, higher values of BASDAI were signiﬁcantly associated with inﬂammatory low
back pain (P < 0.049), alternating buttock pain (P < 0.001), cervical pain (P < 0.001) and hip
involvement (P < 0.001). There was also statistical association between BASDAI scores and
the  peripheral involvement, related to the lower (P = 0.004) and upper limbs (P = 0.025). The
presence of enthesitis was also associated to higher scores of BASDAI (P = 0.040). Positive
HLA-B27 and the presence of cutaneous psoriasis, inﬂammatory bowel disease, uveitis and
urethritis were not correlated with the mean scores of BASDAI. Lower scores of BASDAI were
associated with the use of biologic agents (P < 0.001).
Conclusion: In this heterogeneous Brazilian series of SpA patients, BASDAI was able to
demonstrate “disease activity” in patients with axial as well as peripheral disease.
© 2014 Elsevier Editora Ltda. All rights reserved.
Avaliac¸ão  do  desempenho  do  BASDAI  (Bath  Ankylosing  Spondylitis
Disease  Activity  Index)  numa  coorte  brasileira  de  1.492  pacientes  com
espondiloartrites:  dados  do  Registro  Brasileiro  de  Espondiloartrites  (RBE)
a  b  s  t  r  a  c  talavras-chave:
spondiloartrites
tividade de doenc¸a
Objetivo: Avaliar os resultados da aplicac¸ão do Índice de Atividade de Doenc¸a da Espondilite
Anquilosante de Bath (BASDAI) numa série de pacientes brasileiros com EpA e estabelecer
suas  correlac¸ões com as variáveis especíﬁcas do grupo.
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Métodos: Um protocolo comum de investigac¸ão foi prospectivamente aplicado em 1.492
pacientes brasileiros classiﬁcados como EpA pelos critérios do Grupo Europeu de Estudo das
Espondiloartropatias (ESSG), acompanhados em 29 centros de referência em reumatologia
no  Brasil. Variáveis clínicas, demográﬁcas e índices de doenc¸a foram colhidos. Os valores
totais do BASDAI foram comparados com a presenc¸a das diferentes variáveis.
Resultados: O valor médio do BASDAI foi de 4,20 ± 2,38. Os escores médios do BASDAI foram
mais elevados nos pacientes com forma clínica combinada, comparado às formas axiais
e  periféricas isoladas, nos pacientes do sexo feminino e nos sedentários. Com relac¸ão ao
componente axial, valores mais altos do BASDAI estiveram signiﬁcativamente associados
à  lombalgia inﬂamatória, à dor alternante em nádegas, à dor cervical e ao acometimento
de  coxofemorais. Houve associac¸ão estatística entre os valores do BASDAI e o comprome-
timento periférico, relacionado ao número de articulac¸ões inﬂamadas, tanto dos membros
inferiores quanto dos membros superiores, e às entesites. A positividade do HLA-B27 e a
presenc¸a  de manifestac¸ões extra-articulares não estiveram correlacionadas com os valores
médios do BASDAI. Valores mais baixos do BASDAI estiveram associados ao uso de agentes
biológicos (p < 0,001).
Conclusão: Nesta série heterogênea de pacientes brasileiros com EpA, o BASDAI conseguiu
demonstrar “atividade de doenc¸a” tanto nos pacientes com acometimento axial quanto
naqueles com envolvimento periférico.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
The denomination spondyloarthritis (SpA) deﬁnes a hetero-
geneous group of diseases that share genetic and clinical
characteristics, as well as structural changes in imaging stud-
ies. The positivity of HLA-B27 and the absence of rheumatoid
factor are common to this group of diseases, and the high
frequency of inﬂammatory processes of the spine, sacroiliac
joints and enthesis is considered the main clinical criteria for
the diagnosis of SpA.1 Other clinical manifestations occur in
varying degrees of involvement in the group of SpA; more
often, skin, ocular, intestinal and urogenital injuries and,
less frequently, pulmonary, cardiac, renal and neurological
involvement.1
This group of diseases consists of ankylosing spondylitis
(AS), psoriatic arthritis (PA), reactive arthritis (ReA), arthri-
tis associated with inﬂammatory bowel diseases (also known
as enterophatic arthritis – EA) and undifferentiated spondy-
loarthritis (USpA).1
With the advent of new therapeutic modalities for the
group of SpA, the elaboration of measures of disease activ-
ity that could be used in long-term follow-up was necessary.2
Currently, to evaluate and monitor clinical disease activity in
SpA, the Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI) has been used. This index is obtained by summing
the values of a visual analog scale (VAS) that evaluates six
items, namely: fatigue, axial pain, peripheral pain, enthesi-
tis, duration and intensity of morning stiffness.3 BASDAI does
not use any marker of inﬂammatory activity in its calcula-
tion, since these tests were not standardized at the time of
its proposition.3 BASDAI values are internationally used (BAS-
DAI ≥ 4 is deemed as “high disease activity”) for the indication
of biological agents in the treatment of SpA, when there was
no response to conventional treatment with nonsteroidal anti-
inﬂammatory drugs or with conventional remissive drugs.4,5When the patient reaches BASDAI 50 (improvement in the
BASDAI score of ≥50%) in the ﬁrst 12 weeks of treatment,
this can be considered as a very good clinical response.6 Due
to its importance, BASDAI has been translated and validated
in several languages, including French,7 Swedish,8 German,9
Spanish,10 Turkish,11 Arabic12 and Portuguese.13 Recently, the
Ankylosing Spondylitis Disease Activity Score (ASDAS) was
created14; this index associates the presence of a marker of
inﬂammatory activity, erythrocyte sedimentation rate (ESR)
or C-reactive protein (CRP); nowadays, ASDAS has its cut-
off scores to differentiate “moderate”, “high” and “very high”
activity.15
This paper analyzes the application of BASDAI in a hetero-
geneous Brazilian cohort of 1492 patients with SpA.
Methods
This is a prospective, observational, multicenter study,
conducted with 1492 patients from 29 referral centers par-
ticipating in the Brazilian Registry of Spondyloarthritides
(Registro Brasileiro de Espondiloartrites – RBE). All patients
fulﬁlled the criteria of the European Spondyloarthropathy
Study Group (ESSG).16 Data were collected from June 2006 to
December 2009. RBE participates in the RESPONDIA group
(Registro Iberoamericano de Espondiloartrites), consisting of nine
Latin American countries (Argentina, Brazil, Costa Rica, Chile,
Ecuador, Mexico, Peru, Uruguay and Venezuela) and the two
countries of the Iberian peninsula (Spain and Portugal).
The joint investigation protocol included demographic
variables (gender, race, family history, HLA-B27, exercise),
osteoarticular (inﬂammatory low back pain, buttock pain,
neck pain, hip pain, lower limb arthritis, upper limb arthritis,
enthesitis, dactylitis) and extra-articular (uveitis, inﬂamma-
tory bowel disease [IBD], psoriasis, urethritis) disorders, and
laboratory data (erythrocyte sedimentation rate – ESR and
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Table 2 – Results of BASDAI according to speciﬁc SpA.
% Mean SD P
Primary AS 67.6 4.21 2.36
Psoriatic AS 4.6 4.38 2.32
Enteropathic AS 2.6 4.70 2.41
Psoriatic Arthritis 14.2 4.13 2.47 0.305
USpA 6.8 4.35 2.28
were signiﬁcantly associated with higher mean values of BAS-
DAI. Extra-articular manifestations such as uveitis, psoriasis,
Table 3 – Results of BASDAI according to clinical form.
% Mean SD P
Mixed 48.5 4.50 2.38
Axial 34.5 3.78 2.28 <0.001
Peripheral 11.0 3.87 2.23
Enthesitic 6.0 4.96 2.22
Table 4 – Results of BASDAI according to epidemiological
data.
% Mean SD Pr e v b r a s r e u m a t
-reactive protein – CRP), as well as the treatment (nons-
eroid anti-inﬂammatory drugs – NSAIDs, corticosteroids and
onventional and biological remissive drugs).
For the diagnosis of AS, the New York criteria were used17;
or psoriatic arthritis, the participants had to meet the crite-
ia of Moll and Wright.18 The diagnosis of reactive arthritis
as considered if asymmetric oligoarthritis of the lower limbs
ere present, with enthesopathy and/or inﬂammatory low
ack pain arousing after an enteric or urogenital infection,19
nd spondyloarthritis/arthritis associated with inﬂammatory
owel disease, if the patient had an inﬂammatory axial dis-
rder and/or peripheral joint involvement, associated with
onﬁrmed Crohn’s disease or ulcerative colitis.
BASDAI is a tool for evaluation of disease activity that
ontains six questions.3 The responses were marked on a
orizontal line measuring 10 cm (from 0 to 10 cm), where the
atient evaluates how he feels in relation to each item in the
ast week, marking on the scale: if the patient is ﬁne (“very
ell”), he/she marks zero cm,  gradually increasing until “very
oor”, corresponding to a 10-cm mark. The six questions com-
rising BASDAI are as follows: (1) How would you describe the
egree of fatigue or tiredness you have had?; (2) How would
ou describe the overall level of neck, back and hip pain related
o your illness?; (3) How would you describe the overall level
f pain and edema (swelling) in other joints, apart from neck,
ack and hip?; (4) How would you describe the overall level of
iscomfort you felt to the touch or compression in the painful
egions of your body?; (5) How would you describe the inten-
ity of morning stiffness you have had, from the time you wake
p?; (6) How long does your morning stiffness take, from the
ime you wake up?
tatistical  analysis
he variable categories were compared using2 and Fisher’s
xact tests, and continuous variables were compared using
NOVA. A value of P < 0.05 was considered signiﬁcant; and
.05 > P > 0.10 was considered as a statistical trend.
esults
he mean score of total BASDAI was 4.20 ± 2.38. Among the
ix items that make up the ﬁnal value of BASDAI, the item 2
related to axial pain; 5.05 ± 3.20) had the highest mean, and
he item 3 (related to peripheral component; 3.28 ± 3.18) was
hat with the lowest value. The mean values of BASDAI to all
he questions that make up the index are described in Table 1.
Table 1 – Results of BASDAI per item.
BASDAI Mean Standard
deviation
Total 4.20 2.38
Question 1 4.21 2.99
Question 2 5.05 3.20
Question 3 3.28 3.18
Question 4 4.28 3.34
Question 5 4.59 3.29
Question 6 3.85 3.36Reactive Arthritis 3.4 4.12 2.57
Enteropathic Arthritis 0.8 4.37 3.05
There was no signiﬁcant difference between the mean val-
ues of BASDAI and any speciﬁc disease within the SpA group.
The mean values of BASDAI for each disease within the group
are shown in Table 2. As to the clinical presentation, the
mean values of BASDAI were signiﬁcantly higher in enthesitic
(4.96 ± 2.22) and combined (axial and peripheral; 4.50 ± 2.38)
forms, compared to pure forms, both axial (3.78 ± 2.28) and
peripheral (3.87 ± 2.23) (Table 3).
With regard to demographic variables, BASDAI was signiﬁ-
cantly higher in females (P < 0.001) and in those patients who
did not exercise regularly (P < 0.001). Ethnicity, HLA-B27 and
family history of SpA did not inﬂuence the results of BASDAI
(Table 4).
Numerous clinical variables inﬂuenced BASDAI scores.
Inﬂammatory low back pain (P = 0.039), buttock pain (P < 0.001),
neck pain (P < 0.001), hip pain (P < 0.001), arthritis of lower
(P = 0.004) and upper (P = 0.025) limbs, and enthesitis (P = 0.040)Gender
Male 72.3 3.97 2.95 <0.001
Female 27.7 4.84 3.05
Race
White 67.4 4.03 2.38 0.057
Non-white 32.6 4.30 2.40
Exercise
Yes 40.8 3.89 2.35 <0.001
No 59.2 4.42 2.38
Family history
Yes 18.0 4.32 2.49 0.413
No 82.0 4.18 2.36
HLA-B27
Positive 69.0 4.16 2.33 0.391
Negative 31.0 4.33 2.50
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Table 5 – Results of BASDAI according to clinical data.
% Mean SD P
Inﬂammatory low back pain 0.049
Yes 67.6 4.29 2.31
No 32.4 4.02 2.53
Buttock pain <0.001
Yes 33.1 4.59 2.39
No 66.9 4.01 2.36
Neck pain <0.001
Yes 30.8 4.64 2.32
No 69.2 4.01 2.39
Hip pain <0.001
Yes 25.1  4.63 2.35
No 74.9 4.06 2.38
Arthritis, lower limb 0.004
Yes 48.9 4.38 2.35
No 51.1 4.03 2.30
Arthritis, upper limb
Yes 22.1 4.46 2.40 0.025
No 77.9 4.13 2.37
Enthesitis 0.040
Yes 27.1 4.41 2.41
No 72.9 4.13 2.37
Dactylitis 0.423
Yes 9.1 4.04 2.48
No 90.9 4.22 2.37
Uveitis 0.926
Yes 19.1 4.22 2.53
No 80.9 4.20 2.35
Skin psoriasis 0.849
Yes 17.8 4.23 2.42
No 82.2 4.20 2.38
Inﬂammatory bowel disease 0.106
Yes 4.7 4.67 2.46
No 95.3 4.18 2.38
Urethritis
Table 6 – Results of BASDAI according to treatment.
% Mean SD P
NSAID 0.888
Yes 67.6 4.21 2.35
No 32.4 4.19 2.45
NSAID on-demand 0.713
Yes 24.9 4.16 2.40
No 75.1 4.22 2.38
Corticosteroid 0.297
Yes 35.3 4.29 2.37
No 64.7 4.16 2.39
Methotrexate 0.866
Yes 51.7 4.21 2.32
No 48.3 4.19 2.45
Sulfasalazine 0.934
Yes 44.7 4.21 2.44
No 55.3 4.19 2.34
Biologicals <0.001
Yes 20.4 3.73 2.47
No 79.6 4.32 2.35
Inﬂiximab <0.001
Yes 15.3 3.58 2.50
No 84.7 4.32 2.35
Etanercept 0.104
Yes 2.8 4.78 2.30
No 97.2 4.19 2.38
Adalimumab
Yes 2.3 3.70 2.06 0.164Yes 4.4 4.51 2.57 0.326
No 95.6 4.19 2.37
inﬂammatory bowel disease and urethritis did not inﬂuence
BASDAI scores (Table 5).
With regard to treatment, only the use of anti-TNF biolog-
ical agents was signiﬁcantly associated with lower scores of
BASDAI (P < 0.001), while the use of NSAIDs, corticosteroids,
methotrexate and sulfasalazine did not inﬂuence the values
of BASDAI (Table 6).
Discussion
This study aimed to evaluate the activity of SpA using BAS-
DAI as a clinical activity index; this is a tool traditionally
used in patients with SpA. The results showed that BASDAI
could demonstrate “disease activity”, both in patients with
an axial component as in those with peripheral involvement,
even in patients with SpA but with no diagnosis of AS. In
view of the fact that BASDAI evaluate “axial” (question 2)
and “peripheral” (questions 3 and 4) components, an impor-
tant ﬁnding in this study was represented by the highest
mean scores in patients who  had an involvement described as
“combined” (where the “axial” and “peripheral” components
are observed in the same patient) – a common characteris-
tic of Brazilian patients.20 Similarly, an European multicenterNo 97.7 4.22 2.39
study evaluating 214 patients with SpA found higher values
of BASDAI in those participants with a peripheral component
(4.4 ± 2.3) compared to patients with an isolated axial compo-
nent (3.1 ± 1.9) (P < 0.001).21 Also important was the fact that
the mean values of BASDAI were signiﬁcantly elevated, both in
presence of axial (inﬂammatory low back pain, buttock pain,
neck pain and hip pain) and peripheral (lower and upper joints)
clinical variables, in addition to enthesitis.
In the spectrum of SpA, psoriatic arthritis is that disease
where the peripheral component is most striking. Our  study
showed that BASDAI can also be effective in the evaluation of
patients with PA, as shown in recent studies,22,23 even when
compared to ASDAS.24
With the proposition of ASDAS as a valid method of
assessing disease activity in cases of AS,14,15 it will be impor-
tant to apply this tool to patients with SpA in the second phase
of RBE, to compare its effectiveness versus BASDAI. There is
no established consensus about what is the best method for
assessment of disease activity in patients with AS (if ASDAS
is better than BASDAI). Meanwhile, BASDAI has been shown
as an efﬁcient index in the therapeutic follow-up of patients
with AS.6,25,26 The combination of BASDAI with the functional
index BASFI (Bath Ankylosing Spondylitis Disease Activity
Index)27 made it possible to obtain important characteristics
of patients in the Brazilian Registry of Spondyloarthritides.28
Although representing only 27.7% of the patients, women
had higher mean BASDAI scores, when compared to men.
These results certainly may vary with the population
evaluated.29Regarding the skin color of the patients, there was no signif-
icant difference, as previously described,30 and no signiﬁcant
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ifference in BASDAI scores in relation to HLA-B27, family his-
ory and extra-articular manifestations was found.
In short, BASDAI showed to be an efﬁcient method of
ssessing disease activity in a heterogeneous population of
razilian patients with SpA.
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